Business Wire

Bitmovin Announces Bitmovin Live – IBC Edition

Share

Bitmovin, a leading provider of video infrastructure for digital media companies around the world, today announced Bitmovin Live – IBC Edition, its latest, live virtual event series with tech sessions that will be of interest to streaming/OTT and technology industry executives, in addition to developers across the globe. The focus for this series of events is innovative ways to reduce the costs of video distribution and app development and optimizing video workflows to elevate the viewer experience. Bitmovin Live – IBC Edition will take place from September 8th – 24th. All sessions will be available on-demand for those not able to view the events live. More information on Bitmovin Live – IBC Edition, and to register, visit: https://www.bitmovin.com/ibc-edition

“The Bitmovin Live series has demonstrated how it has been possible to adapt quickly and effectively to an online-only conference format in response to COVID-19,” said Ben Dales, Digital Media Manager from the broadcast and media technology industry trade group IABM. “IABM has long been a champion of collaboration, and with Bitmovin Live - IBC Edition, we are impressed to see Bitmovin expand its involvement to partners, industry leaders, and sometimes even competitors in the spirit of providing a place for the community to thrive despite the global challenges.”

The marquee event kicks-off on September 10th with executives from Roku, YouTube, Sky Studios, ViacomCBS and Bitmovin discussing “Succeeding in the Global Streaming Economy.” Variety International Editor Manori Ravindran will moderate the conversation that will be hosted in the “Variety Streaming Room” presented by Bitmovin on Sept. 10 at 9 a.m. PT/12 p.m. ET. To sign up, please visit: Variety Streaming Room: Succeeding in the Global Streaming Economy

The closing session, moderated by IABM on September 23rd, will be “Innovating SVOD and AVOD strategies for reshaped media landscape.” Sign up at Innovating AVOD and SVOD strategies

Bitmovin is dedicated to using new and innovative ways of interacting with event participants. As a compliment to the usual programming of webinars, tech talks and panels, it has created a “Virtual VR Event Booth,” a space that can bring prospects and customers closer to Bitmovin’s employees and services.

“The ‘Virtual VR Event Booth’ will showcase a high-level overview of Bitmovin origins, the value the company brings, as well as a look at the solutions and products that are offered,” said Jamie Attfield, Head of Design at Bitmovin. “Attendees are also free to explore an assortment of collateral pieces that can be downloaded to their machines and devices for further reading. This experience will be accessible on mobile, desktop and Oculus Quest, bringing a new perspective on how the company can communicate in the digital realm.”

About Bitmovin:

Built for technical professionals in the OTT video market, Bitmovin’s software solutions help you optimize customer operations and reduce time-to-market, resulting in the best viewer experience imaginable. This is achieved through our device reach, flexible and scalable integration, and commitment to supporting our customers. Learn more at www.bitmovin.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Glenn Mendel
Escalate Communications
(e) glenn@escalatecommunications.com
(p) +1 760-798-1563

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye